The purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
9
2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
Westside Family Medical Center
Kalamazoo, Michigan, United States
Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)
Time frame: Up to 2 hours post-dose
Time to first perceptible relief
Is defined as the time when the subject presses the first stopwatch
Time frame: Up to 2 hours post-dose
Time to first perceptible relief confirmed
The subjects would meet this outcome if they answer "yes" when asked directly after stopping the first stopwatch, if they marked a "1" on the relief pain scale or if they stopped the 2nd stop watch.
Time frame: Up to 2 hours post-dose
Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)
Time frame: At baseline, 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication
Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)
Time frame: At 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication
Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)
Time frame: Up to 1 hour
Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)
Time frame: Up to 2 hours
Summed time weighted total pain relief scores over first hour (TOTPAR0-1)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 1 hour
Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)
Time frame: Up to 2 hours
Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)
Time frame: Up to 1 hour
Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)
Time frame: Up to 2 hours
Time to first intake of rescue medication
Time frame: Up to 2 hours
Cumulative proportion of subjects taking rescue medication by time point
Time frame: Up to 2 hours
Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent
Time frame: At 2 hours post-dose or immediately before the first intake of rescue medication, whichever is earlier
Safety variable will be summarized using descriptive statistic based on adverse events collection
Time frame: Up to 5 days post-dose